Bio-Tissue (www.biotissue.com), a business unit of TissueTech, Inc., develops and markets regenerative therapies that allow eye care professionals to advance the standard of care for treating the ocular surface. Its core products include cryopreserved amniotic membrane and umbilical cord-based tissue with innate therapeutic actions scientifically proven to heal the ocular surface. The Company’s proprietary CryoTek® preservation method ensures the tissue retains its biologic activity and healing components. To date, more than 300,000 allografts have been transplanted collectively by Bio-Tissue and sister company Amniox Medical (TissueTech business units).